078140.Kq

The company maintains a relatively strong liquidity position, with a current ratio of 5.44, indicating that it has more than five times the current assets to cover its current liabilities. However, the firm has a negative net cash position after subtracting total debt, which raises concerns about its short-term liquidity. The price-to-book ratio of 0.77 suggests that the company is trading at a discount to its book value, potentially indicating undervaluation or concerns about asset quality.

In terms of profitability, the company's return on equity (ROE) of 7.12% is a key metric for assessing its ability to generate returns for shareholders. This ROE is below the typical industry benchmark for pharmaceutical firms, which often exceed 10%. The return on assets (ROA) of 3.8% also suggests that the company is not efficiently utilizing its assets to generate profits compared to industry peers. The operating margin, calculated as operating income divided by revenue, is 7.13%, which is in line with the median for the pharmaceutical industry.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The firm's revenue is primarily derived from the sale of prescription drugs, with no significant diversification into other therapeutic areas or product lines.

Looking at the company's growth trajectory, the outlook for the current fiscal year is modest, with revenue expected to remain relatively flat. The company's capital expenditures are high, with a negative free cash flow of -24.23 billion KRW, indicating that the firm is investing heavily in its operations. This level of investment may be necessary to maintain or expand its product portfolio in a competitive market. The company's operating cash flow of 8.91 billion KRW is positive but not sufficient to cover its capital expenditures.

The company faces several risk factors, including liquidity concerns due to its negative net cash position and the potential for dilution, although the risk of dilution is currently assessed as low. The firm's debt-to-equity ratio of 0.52 is relatively moderate, but the high level of long-term debt (73.46 billion KRW) could become a burden if interest rates rise or if the company's revenue growth slows. The company has not disclosed any recent equity offerings or share buybacks that would significantly impact its capital structure.

Recent events, as disclosed in the company's financial filings, include a significant increase in capital expenditures and a corresponding decrease in free cash flow. The company has not issued any new debt or equity in the recent period, and there are no material changes in its business operations or strategic direction reported in the latest filings. The company's recent performance has been stable, with no major disruptions in its supply chain or regulatory compliance issues.